(Q43781411)

English

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

scientific article published in March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia (English)

1 reference

Europe PubMed Central

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sue K Cammarata

object named as

Sue K Cammarata

2

0 references

Richard G. Wunderink

object named as

Richard G Wunderink

1

0 references

4

object named as

Marin H Kollef

1 reference

Europe PubMed Central

26 November 2017

author name string

Thomas H Oliphant

3

1 reference

Europe PubMed Central

26 November 2017

Linezolid Nosocomial Pneumonia Study Group

5

1 reference

Europe PubMed Central

26 November 2017

publication date

1 March 2003

1 reference

Europe PubMed Central

26 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

26 November 2017

25

1 reference

Europe PubMed Central

26 November 2017

3

1 reference

Europe PubMed Central

26 November 2017

980-992

1 reference

Europe PubMed Central

26 November 2017

Nosocomial infections in combined medical-surgical intensive care units in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Linezolid-induced pure red blood cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombocytopenia associated with linezolid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring serum vancomycin levels: climbing the mountain because it is there?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2803%2980118-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(03)80118-2

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43781411&oldid=2103277719"